Celcuity presents a high-risk, high-optionality profile: 58.8% of upside headroom to the analyst consensus target with an 8.4-to-1 reward-to-risk ratio reflects strong analyst conviction in the lead pipeline program, but the company burns cash with negative free cash flow, quality scores among the weakest in the universe, a price that has plunged to an RSI of 17, and 30% short interest — a combination that demands a successful clinical catalyst to bridge the gap between current price and the fundamental case.
Thesis pillars
- Single Pipeline Asset Concentration→Stable
- Cash Burning Quality Near Floor→Stable
- Capitulation Risk Vs Rising Long Term Trend→Stable
- +1 more pillar — see the Why tab for full reasoning
Celcuity Inc. (CELC) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $107.95: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 33%; Below-average business quality.
Celcuity is a clinical-stage biotech developing gedatolisib, a pan-class I PI3K/mTOR inhibitor targeting HR+/HER2- advanced breast cancer. The company has no product revenue; the FDA accepted the gedatolisib NDA in January 2026 with Priority Review and a PDUFA target date of... Read more
Sell if holding. Engine safety override at $107.95: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 33%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 41d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Celcuity Inc.
About Celcuity Inc.
Celcuity's lead clinical asset, gedatolisib, received FDA Priority Review acceptance in January 2026 with a PDUFA date of July 17, 2026 — the culmination of a Phase 3 VIKTORIA-1 program that enrolled 754 subjects across nearly 200 global sites. The PIK3CA wild-type cohort reported topline data in July 2025, showing a hazard ratio of 0.24 for the gedatolisib triplet versus fulvestrant. VIKTORIA-2, a second Phase 3 trial, dosed its first patient in July 2025.
Celcuity generates no product revenue and finances operations through equity and debt. The company carried $338.8 million in aggregate principal indebtedness at year-end 2025, including $130.0 million in secured Term Loans and $201.3 million in 2.750% Senior Notes due 2031. Gedatolisib is licensed from Pfizer; Celcuity built out regulatory and clinical capabilities but has not yet established commercial manufacturing or sales infrastructure. The anticipated revenue model — IV oncology drug sales to hospitals and cancer centers for HR+/HER2- patients who progressed on CDK4/6 therapy — competes with alpelisib (PI3Kα inhibitor) and capivasertib (AKT inhibitor), both of which gedatolisib outperformed on hazard ratios in the VIKTORIA-1 wild-type cohort.
Show full overview
The company's entire near-term value rests on the July 17, 2026 PDUFA date. The PIK3CA mutant-type cohort (VIKTORIA-1 cohort 2) had not yet reported as of the 10-K — topline data were expected in Q2 2026 — and VIKTORIA-2 is still enrolling. In June 2026, Celcuity disclosed via Form 8-K an entry into an underwriting agreement for $575 million in 0.250% Convertible Senior Notes due 2032, adding debt in anticipation of a commercial launch. If the FDA issues a Complete Response Letter, the combined existing and new debt obligations could weigh on the capital structure before any product revenue is generated.
See also: Healthcare · Biotechnology
From Celcuity Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-06Recent Developments — Celcuity Inc.
Material events (past 30 days)
- 8K Jun 8, 2026 MEDIUM Item 1.01: Celcuity entered underwriting agreement June 3, 2026 for $575M of 0.250% Convertible Senior Notes due 2032 (Jefferies, JPMorgan, TD Securities, Guggenheim); $75M overallotment exercised June 4; issuance completed June 8, 2026.
- 8K Jun 8, 2026 MEDIUM Item 2.03: Creation of $575M direct financial obligation: 0.250% Convertible Senior Notes due 2032, issued June 8, 2026 under indenture with U.S. Bank Trust Company, National Association as trustee.
Latest news
- NEWS Reported Earlier, Celcuity Prices Upsized $500M Convertible Notes Offering (Up From Prior $400M) — benzinga Jun 4, 2026 positive
- NEWS Craig-Hallum Maintains Buy on Celcuity, Lowers Price Target to $171 — benzinga Jun 3, 2026 neutral
- NEWS Wells Fargo Maintains Overweight on Celcuity, Lowers Price Target to $166 — benzinga Jun 3, 2026 neutral
- NEWS Palo Alto Networks To Rally Nearly 70%? Here Are 10 Notable Analyst Calls From Wednesday — benzinga Jun 3, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on Celcuity, Lowers Price Target to $145 — benzinga Jun 3, 2026 positive
Generated 2026-07-06T05:40:26Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinegedatolisib10-K Item 1A: 'Our near-term revenue prospects depend on the success of our initial drug product, gedatolisib'
Material Events(8-K, last 90d)
- 2026-06-08Item 1.01MEDIUMCelcuity entered underwriting agreement June 3, 2026 for $575M of 0.250% Convertible Senior Notes due 2032 (Jefferies, JPMorgan, TD Securities, Guggenheim); $75M overallotment exercised June 4; issuance completed June 8, 2026.SEC filing →
- 2026-06-08Item 2.03MEDIUMCreation of $575M direct financial obligation: 0.250% Convertible Senior Notes due 2032, issued June 8, 2026 under indenture with U.S. Bank Trust Company, National Association as trustee.SEC filing →
- 2026-05-20Item 5.02LOW8-K/A amendment re Feb 11, 2026: Charles (Chip) R. Romp appointed as independent director filling vacancy from board expansion (7 to 8 members); subsequently added to Compensation Committee and N&CG Committee on May 14, 2026. No officer departure.SEC filing →
- 2026-05-18Item 5.02LOWAt May 14, 2026 Annual Meeting, stockholders approved the 2026 Stock Incentive Plan (3,000,000 shares authorized). No executive officer departure or appointment of new executives.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $107.95: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 33%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $100.39. Score 5.2/10, moderate confidence.
Take-profit target: $139.75 (+29.5% upside). Prior stop was $100.39. Stop-loss: $100.39.
Concentration risk — Pipeline: gedatolisib; Quality below floor (1.4 < 4.0).
Celcuity Inc. trades at a P/E of N/A (forward 145.9). TrendMatrix value score: 5.4/10. Verdict: Sell.
18 analysts cover CELC with a consensus score of 4.3/5. Average price target: $161.
What does Celcuity Inc. do?Celcuity is a clinical-stage biotech developing gedatolisib, a pan-class I PI3K/mTOR inhibitor targeting HR+/HER2-...
Celcuity is a clinical-stage biotech developing gedatolisib, a pan-class I PI3K/mTOR inhibitor targeting HR+/HER2- advanced breast cancer. The company has no product revenue; the FDA accepted the gedatolisib NDA in January 2026 with Priority Review and a PDUFA target date of July 17, 2026. Funding comes from equity and debt, including $338.8 million in aggregate principal indebtedness as of December 31, 2025.